Structure Therapeutics (NASDAQ:GPCR) Reaches New 52-Week Low - Here's What Happened

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) hit a new 52-week low on Friday . The company traded as low as $19.11 and last traded at $19.16, with a volume of 42940 shares trading hands. The stock had previously closed at $19.94.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GPCR shares. JMP Securities reaffirmed a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target for the company. Finally, William Blair initiated coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Price Performance

The business has a fifty day moving average of $23.99 and a 200 day moving average of $31.00. The stock has a market capitalization of $905.45 million, a price-to-earnings ratio of -21.34 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. On average, equities research analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC grew its position in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Structure Therapeutics during the fourth quarter worth about $34,000. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth about $40,000. Finally, Virtus ETF Advisers LLC boosted its stake in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after purchasing an additional 455 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.